Lyell Immunopharma
Lyell Immunopharma raises $425M Series C at $1.4B valuation
Quick Facts
Lyell Immunopharma: Series C Funding Round
Lyell Immunopharma has successfully raised $425M in Series C funding, reaching a valuation of $1.4B.
Company Overview
T-cell reprogramming for solid tumors
Funding Details
The Series C round was led by GV, with participation from F-Prime Capital, Bain Capital Life Sciences, Patient Square Capital, Bristol Myers Squibb.
Company Information
- Headquarters: 201 Haskins Way, South San Francisco, CA 94080
- Founded: 2018
- Employees: 300+
- Category: Biotech
Investment
Lyell Immunopharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- GV: Verified investor in Series C
- F-Prime Capital: Verified investor in Series C
- Bain Capital Life Sciences: Verified investor in Series C
- Patient Square Capital: Verified investor in Series C
- Bristol Myers Squibb: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...